Please Wait
Applying Filters...

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

NFlection is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks like keratinocytic epidermal nevi and nevi sebacei. The company's focus involves addressing RAS-mediated disorders caused by the abnormal activation of the Ras/Raf/MEK/ERK pathway. NFlection is actively deve...
NFlection is a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for patients with neurofibromatosis type 1, immunosuppressant-mediated squamous cell carcinoma, and congenital birthmarks like keratinocytic epidermal nevi and nevi sebacei. The company's focus involves addressing RAS-mediated disorders caused by the abnormal activation of the Ras/Raf/MEK/ERK pathway. NFlection is actively developing first-in-class MEK (mitogen-activated protein kinase kinase) inhibitors for the topical treatment of these conditions.

List your booth number for exhibitions, ask us